ArticleAdvanced healthcare materials2022
Injectable Extracellular Matrix Microparticles Promote Heart Regeneration in Mice with Post-ischemic Heart Injury.
Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy.Frontiers in bioengineering and biotechnology · 2022Pooled it
- Signaling pathways regulating cardiac regeneration.Cell regeneration (London, England) · 2026Review
- Bench to Bedside: Insights from Large Animal Models and Emerging Clinical Trials of Endogenous Cardiac Regeneration and Repair.Journal of cardiovascular translational research · 2026Review
- Cardiac-Derived ECM Microspheres for Enhanced hiPSC-CMs Maturation.Advanced functional materials · 2026Article
- Review
- Hydrogels loaded with different substances for treating heart failure: a promising therapy.Frontiers in cardiovascular medicine · 2026Review
- A bioactive heart-derived ECM hydrogel potentiates Astragaloside IV-mediated microvascular regeneration.Frontiers in bioengineering and biotechnology · 2026Article
- Extracellular-Matrix-Based Materials from Decellularized Tissue: Opportunities, Challenges, and Future Directions in Regenerative Medicine.Advanced healthcare materials · 2026Review
- SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation.Nature cancer · 2025Article
- Self-assembled extracellular matrix-lipid nanoparticle composite for site-specific siRNA delivery to improve cardiac repair post-myocardial infarction.Materials today. Bio · 2025Article
- Development of a decellularized extracellular matrix-derived wet adhesive for sustained drug delivery and enhanced wound healing.Materials today. Bio · 2025Article
- The application of tissue engineering strategies for uterine regeneration.Materials today. Bio · 2025Review
- Cardiac repair using regenerating neonatal heart tissue-derived extracellular vesicles.Nature communications · 2025Article
- Lab-grown, 3D extracellular matrix particles improve cardiac function and morphology in myocardial ischemia.American journal of physiology. Heart and circulatory physiology · 2025Article
- Recent advancements in smart responsive tissue adhesives for medical applications.Frontiers in medicine · 2025Review
- Tunable methacrylated decellularized heart matrix: a versatile scaffold for cardiac tissue engineering.Frontiers in bioengineering and biotechnology · 2025Article
- The considerations on selecting the appropriate decellularized ECM for specific regeneration demands.Materials today. Bio · 2024Review
- Decellularized extracellular matrix materials for treatment of ischemic cardiomyopathy.Bioactive materials · 2024Review
- Constructing Tumor Organoid-like Tissue for Reliable Drug Screening Using Liver-Decellularized Extracellular Matrix Scaffolds.ACS omega · 2024Article
- The Current State of Extracellular Matrix Therapy for Ischemic Heart Disease.Medical sciences (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Ischemic heart injury causes permanent cardiomyocyte loss and fibrosis impairing cardiac function. Tissue derived biomaterials have shown promise as an injectable treatment for the post-ischemic heart. Specifically, decellularized extracellular matrix (dECM) is a protein rich suspension that forms a therapeutic hydrogel once injected and improves the heart post-injury response in rodents and pig models. Current dECM-derived biomaterials are delivered to the heart as a liquid dECM hydrogel precursor or colloidal suspension, which gels over several minutes. To increase the functionality of the dECM therapy, an injectable solid dECM microparticle formulation derived from heart tissue to control sizing and extend stability in aqueous conditions is developed. When delivered into the infarcted mouse heart, these dECM microparticles protect cardiac function promote vessel density and reduce left ventricular remodeling by sustained delivery of biomolecules. Longer retention, higher stiffness, and slower protein release of dECM microparticles are noted compared to liquid dECM hydrogel precursor. In addition, the dECM microparticle can be developed as a platform for macromolecule delivery. Together, the results suggest that dECM microparticles can be developed as a modular therapy for heart injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.